Contact

Long Waypoint 65 Home About Services Research Digest Safety Considerations Methods & Measures Contact Evidence, uncertainty, and risk Ibogaine Brain Research News And Analysis A plainspoken guide to what current brain research can—and cannot—say about ibogaine, addiction, neuroplasticity, clinical trials, and safety. Ibogaine remains scientifically interesting and clinically hazardous. No completed, adequately controlled randomized trial has established superiority over standard addiction care. Careful interpretation matters when early neuroscience meets urgent clinical need. Ibogaine is a psychoactive indole alkaloid derived primarily from Tabernanthe iboga , a West African shrub with traditional use in Bwiti religious and cultural practices. It is often discussed as a possible intervention for opioid addiction, but its brain effects and safety profile demand much more caution than a “reset” narrative suggests. As a natural plant alkaloid, ibogaine enters a complex area of neurobiology: receptor binding, metabolism, altered consciousness, withdrawal symptoms, and possible changes in learning. The historical and pharmacological overview of ibogaine is useful context, but it does not substitute for clinical evidence. This page separates findings from animal models, early human observations, and questions still awaiting controlled clinical trials. It is not a guide to self-treatment, detox, or dosing. What is established Ibogaine can affect multiple neurotransmitter systems and can create meaningful cardiovascular risk, especially without screening and monitoring. What is emerging Neuroplasticity, neural pathways, functional MRI, and electrophysiology are becoming more directly testable in human research. What is unresolved Whether observed changes translate into durable benefit for substance use disorder, and for whom, remains uncertain. Mechanisms, not shortcuts The science behind ibogaine's neurological effects Ibogaine is metabolized into noribogaine, a longer

Contact

A careful place for feedback.